Starling Oncology, Inc.
STLN· Nasdaq
STLNStarling Oncology, Inc.
Filed Aug 16, 2021 · 10-Q · 47 days after period end · 0001104659-21-106369
| Metric | Q2 2021 | Q2 2020 |
|---|---|---|
| Revenue | $49.84M | — |
| Net Income | -$6.12M | -$115.74K |
| EPS Diluted | $0.05 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Starling Oncology, Inc. · CIK 1799191 · Engraved from SEC EDGAR
ended Jun 30, 2021 · filed Aug 16, 2021 · 47 d after period end
